Daré Bioscience, Inc. (DARE): Price and Financial Metrics
GET POWR RATINGS... FREE!
DARE Stock Price Chart Interactive Chart >
DARE Price/Volume Stats
|Current price||$1.13||52-week high||$2.51|
|Prev. close||$1.13||52-week low||$0.92|
|Day high||$1.17||Avg. volume||1,912,128|
|50-day MA||$1.36||Dividend yield||N/A|
|200-day MA||$1.59||Market Cap||95.72M|
Daré Bioscience, Inc. (DARE) Company Bio
DarÃ© Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company intends to develop therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single application that completed Phase 3 clinical trials; Ovaprene, a hormone-free, monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone replacement therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214 injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is based in San Diego, California.
Most Popular Stories View All
DARE Latest News Stream
|Loading, please wait...|
DARE Latest Social Stream
View Full DARE Social Stream
Latest DARE News From Around the Web
Below are the latest news stories about Dare Bioscience Inc that investors may wish to consider to help them evaluate DARE as an investment opportunity.
The following slide deck was published by Daré Bioscience, Inc. in conjunction with this event....
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in the following upcoming conferences: 2022 BIO CEO & Investor ConferenceFebruary 14-17, 2022, New York Marriott Marquis and VirtualIn-person Presentation Monday, February 14, 2022 at 2:15 p.m. EST SVB Leerink Virtual 11th Annual Global Healthcare ConferenceFebruary 14-1
Analysts Have Conflicting Sentiments on These Healthcare Companies: Zogenix (ZGNX) and Daré Bioscience (DARE)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zogenix (ZGNX – Research Report) and Daré Bioscience (DARE – Research Report). Zogenix (ZGNX) In a report released today, Serge Belanger from Needham downgraded Zogenix to Hold. The company's shares closed last Wednesday at $26.19. According to TipRanks.
Dawson James analyst Jason Kolbert maintained a Buy rating on Daré Bioscience (DARE – Research Report) on November 23 and set a price target of $3.00. The company's shares closed last Thursday at $1.84. According to TipRanks.com, Kolbert is a 4-star analyst with an average return of 5.0% and a 41.9% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Daré Bioscience with a $3.67 average price target, a 102.8% upside from current levels.
Dawson James analyst Jason Kolbert maintained a Buy rating on Daré Bioscience (DARE – Research Report) on December 8 and set a price target of $3.00. The company's shares closed last Thursday at $1.84. According to TipRanks.com, Kolbert is a 4-star analyst with an average return of 5.0% and a 41.9% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. Daré Bioscience has an analyst consensus of Strong Buy, with a price target consensus of $3.67, implying a 102.8% upside from current levels. In a report issued on December 8, H.C.
DARE Price Returns